Literature DB >> 10571023

Glycoconjugates in Leishmania infectivity.

A Descoteaux1, S J Turco.   

Abstract

Leishmaniasis is a major health problem to humans and is caused by one of the world's major pathogens, the Leishmania parasite. These protozoa have the remarkable ability to avoid destruction in hostile environments they encounter throughout their life cycle. That Leishmania parasites have adapted to not only survive, but to proliferate largely is due to the protection conferred by unique glycoconjugates that are either on the parasites' cell surface or secreted. Most of these specialized molecules are members of a family of phosphoglycans while others are a family of glycosylinositol phospholipids. Together they have been implicated in a surprisingly large number of functions for the parasites throughout their life cycle and, therefore, are key players in their pathogenesis. This review summarizes the biological roles of these glycoconjugates and how they are believed to contribute to Leishmania survival in destructive surroundings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571023     DOI: 10.1016/s0925-4439(99)00065-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  65 in total

1.  Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response.

Authors:  C Kébaïer; H Louzir; M Chenik; A Ben Salah; K Dellagi
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Simple and efficient synthesis of 5'-aryl-5'-deoxyguanosine analogs by azide-alkyne click reaction and their antileishmanial activities.

Authors:  Pierre Daligaux; Sébastien Pomel; Karine Leblanc; Philippe M Loiseau; Christian Cavé
Journal:  Mol Divers       Date:  2016-01-11       Impact factor: 2.943

3.  Hydrophilic Acylated Surface Protein A (HASPA) of Leishmania donovani: Expression, Purification and Biophysico-Chemical Characterization.

Authors:  Manoj Kumar; Kishu Ranjan; Vijay Singh; Chandramani Pathak; Anju Pappachan; Desh Deepak Singh
Journal:  Protein J       Date:  2017-08       Impact factor: 2.371

Review 4.  Survival of protozoan intracellular parasites in host cells.

Authors:  Patrícia Leirião; Cristina D Rodrigues; Sónia S Albuquerque; Maria M Mota
Journal:  EMBO Rep       Date:  2004-12       Impact factor: 8.807

5.  Leishmania donovani Lipophosphoglycan Increases Macrophage-Dependent Chemotaxis of CXCR6-Expressing Cells via CXCL16 Induction.

Authors:  Visnu Chaparro; Louis-Philippe Leroux; Aude Zimmermann; Armando Jardim; Brent Johnston; Albert Descoteaux; Maritza Jaramillo
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

6.  Disruption of mannose activation in Leishmania mexicana: GDP-mannose pyrophosphorylase is required for virulence, but not for viability.

Authors:  A Garami; T Ilg
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

7.  The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts.

Authors:  Gerald F Späth; L A Garraway; Salvatore J Turco; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

Review 8.  Leishmania interferes with host cell signaling to devise a survival strategy.

Authors:  Suvercha Bhardwaj; Neetu Srivastava; Raki Sudan; Bhaskar Saha
Journal:  J Biomed Biotechnol       Date:  2010-04-08

9.  Differential midgut attachment of Leishmania (Viannia) braziliensis in the sand flies Lutzomyia (Nyssomyia) whitmani and Lutzomyia (Nyssomyia) intermedia.

Authors:  Rodrigo P Soares; Carina Margonari; Nágila C Secundino; Maria E Macêdo; Simone M da Costa; Elizabeth F Rangel; Paulo F Pimenta; Salvatore J Turco
Journal:  J Biomed Biotechnol       Date:  2010

10.  The Leishmania donovani lipophosphoglycan excludes the vesicular proton-ATPase from phagosomes by impairing the recruitment of synaptotagmin V.

Authors:  Adrien F Vinet; Mitsunori Fukuda; Salvatore J Turco; Albert Descoteaux
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.